The biotech received some positive news from a top regulator. That organization released a partial clinical hold on a key investigational drug. On Thursday, Avidity announced that the U.S. Food and ...

Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity. Novartis is acquiring ...

Evercore ISI downgraded Avidity Biosciences (RNA) to In Line from Outperform with a price target of $72, up from $65. Novartis (NVS) has agreed to ...

Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Shares of Avidity Biosciences Inc. RNA gained about 2.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic ...

Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...

LA JOLLA, Calif., Jan. 11, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody ...

Avidity Biosciences Inc. said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. in a deal that will see Avidity receive $100 million upfront with the potential to ...

Affinity and avidity are two terms used in immunology and microbiology to describe binding strength between an antibody and antigen. Because both affinity and avidity involve binding strength, the two ...